[HTML][HTML] Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Q Lu, Z Zhang, H Li, K Zhong, Q Zhao, Z Wang… - Journal of …, 2021 - Springer
Background The outbreak and pandemic of coronavirus SARS-CoV-2 caused significant
threaten to global public health and economic consequences. It is extremely urgent that …

A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential

J Gai, L Ma, G Li, M Zhu, P Qiao, X Li, H Zhang… - MedComm, 2021 - Wiley Online Library
Abstract The coronavirus disease 2019 (COVID‐19) pandemic has become a serious
burden on global public health. Although therapeutic drugs against COVID‐19 have been …

An intelligent face mask integrated with high density conductive nanowire array for directly exhaled coronavirus aerosols screening

Q Xue, X Kan, Z Pan, Z Li, W Pan, F Zhou… - Biosensors and …, 2021 - Elsevier
The current ongoing outbreak of Coronavirus Disease 2019 (COVID-19) has globally
affected the lives of more than one hundred million people. RT-PCR based molecular test is …

[HTML][HTML] Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics

L Chitsike, P Duerksen-Hughes - Virology Journal, 2021 - Springer
The COVID-19 pandemic has put healthcare infrastructures and our social and economic
lives under unprecedented strain. Effective solutions are needed to end the pandemic while …

Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies

L Du, Y Yang, X Zhang, F Li - Nanoscale, 2022 - pubs.rsc.org
COVID-19 has caused a global pandemic and millions of deaths. It is imperative to develop
effective countermeasures against the causative viral agent, SARS-CoV-2 and its many …

NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies

TR Wagner, E Ostertag, PD Kaiser, M Gramlich… - EMBO …, 2021 - embopress.org
In light of the COVID‐19 pandemic, there is an ongoing need for diagnostic tools to monitor
the immune status of large patient cohorts and the effectiveness of vaccination campaigns …

[PDF][PDF] A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations

F Bertoglio, V Fühner, M Ruschig, PA Heine, L Abassi… - Cell reports, 2021 - cell.com
The novel betacoronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)
causes a form of severe pneumonia disease called coronavirus disease 2019 (COVID-19) …

[HTML][HTML] Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2

S Jiang, X Zhang, L Du - Expert Opinion on Therapeutic Targets, 2021 - Taylor & Francis
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in
December 2019 and causes coronavirus (CoV) disease 2019 (COVID-19). The virus …

Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes

H Mikolajek, M Weckener… - Proceedings of the …, 2022 - National Acad Sciences
Camelid single-domain antibodies, also known as nanobodies, can be readily isolated from
naïve libraries for specific targets but often bind too weakly to their targets to be immediately …

[HTML][HTML] An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation

M Schoof, B Faust, RA Saunders, S Sangwan, V Rezelj… - BioRxiv, 2020 - ncbi.nlm.nih.gov
Without an effective prophylactic solution, infections from SARS-CoV-2 continue to rise
worldwide with devastating health and economic costs. SARS-CoV-2 gains entry into host …